82: Regenerating Muscles: The Future of Autologous Cell-based Therapy with Deana Mohr - Part 2

Dive into the cutting-edge world of autologous cell-based therapy with Deana Mohr, CEO and co-founder of MUVON Therapeutics, spin-off from the University of Zurich. In this eye-opening episode, discover how MUVON Therapeutics’ innovative approach to muscle regeneration is revolutionizing treatments for stress urinary incontinence and beyond.

Learn how her team is tackling the challenges of bringing personalized medicine to market at scale, from navigating complex regulations to automating production processes.

Listeners will gain invaluable insights on:

1. Strategies for engaging with regulatory bodies to advance novel therapies
2. The crucial role of automation in making cell therapies accessible and affordable
3. Building successful partnerships to accelerate biotech innovation

Whether you're a scientist, investor, or healthcare professional, this episode offers a fascinating glimpse into the future of regenerative medicine. Tune in to explore how Deana's vision of "copy-paste" therapy production could transform millions of lives and reshape the biotech landscape!

Connect with Deana Mohr:

LinkedIn: https://www.linkedin.com/in/deana-mohr-haralampieva-95a9a5a4

MUVON Therapeutics: https://www.muvon-therapeutics.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show